AstraZeneca-Amgen drug could widen treatment options for severe asthma


2/2

© Reuters. The AstraZeneca office building in Brussels

2/2

By Pushkala Aripaka

(Reuters) – AstraZeneca (NASDAQ:) and Amgen (NASDAQ:)’s experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.

The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study, which had roughly 1,000 patients who were already receiving standard care, the drugmakers said on Friday.

It also worked in a subgroup of volunteers with low levels of eosinophils, a type of white blood cell, detailed data presented at a virtual meeting of the American Academy of Allergy Asthma and Immunology showed.

The drug cut the risk of exacerbations by 70% in patients with more than or equal to 300 eosinophils per microlitre of blood, which is the baseline, by 41% in those with less than 300 cells, and 39% with less than 150 cells.

Eosinophils are associated with swelling and narrowing of airways that could make asthma attacks worse. The respiratory condition can be triggered and turn severe by many factors, including eosinophil count and allergies.

Tezepelumab works by blocking a type of immune protein called TSLP, found in the linings of the lungs. TSLP belongs to the cytokine group responsible for sounding an alarm to the body’s immune system and can also trigger inflammation.

The biologic drug, if approved, will compete with AstraZeneca’s own Fasenra and Regeneron’s Dupixent.

AstraZeneca’s Fasenra, which garnered almost $1 billion in sales last year, is a strong contender in the market to treat severe eosinophilic asthma, but tezepelumab would help the company branch out to treat non-eosinophilic patients.

READ  FCA pays up to keep its Jeep brand on CR7 Juve jersey

“Alongside Fasenra, we think that having two really strong complimentary, robust biologics in this space will actually expand use in eligible patients,” Richard Marshall, global head of late respiratory and immunology at AstraZeneca told Reuters.

Tezepelumab also improved lung function in patients, helped control asthma better and cut the risk of hospitalisations or emergency visits by 79%, data showed.

AstraZeneca’s Marshall said the study results will form part of regulatory submissions expected in the first half of 2021.

Roughly 339 million people suffer from asthma worldwide, 10% of whom have severe forms of the condition.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here